This slide presents the distribution of diagnoses of HIV infection among adults and adolescents diagnosed from 2006 through 2009, by transmission category in the 40 states and 5 U.S. dependent areas with confidential name-based HIV infection reporting since at least January 2006.   The estimated number of diagnoses of HIV infection among adults and adolescents exposed through male-to-male sexual contact increased by 14% from 21,156 in 2006 to 24,132 diagnoses in 2009. The number of diagnoses among adults and adolescents exposed through injection drug use decreased by 26% (from 5,642 in 2006 to 4,172 in 2009) and among persons exposed through male-to-male sexual contact and injection drug use, diagnoses decreased by 20% (from 1,448 in 2006 to 1,157 in 2009). The number of diagnoses of HIV infection among adults and adolescents exposed through heterosexual contact remained stable during this time period. The remaining diagnoses of HIV infection were those attributed to hemophilia or the receipt of blood or blood products, and those in persons without an identified risk factor. The following 40 states have had laws or regulations requiring confidential name-based HIV infection reporting since at least January 2006: Alabama, Alaska, Arizona, Arkansas, Colorado, Connecticut, Florida, Georgia, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Michigan, Minnesota, Mississippi, Missouri, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Pennsylvania, South Carolina, South Dakota, Tennessee, Texas, Utah, Virginia, West Virginia, Wisconsin, and Wyoming. The 5 U.S. dependent areas include American Samoa, Guam, the Northern Mariana Islands, Puerto Rico and the U.S. Virgin Islands. Data include persons with a diagnosis of HIV infection regardless of stage of disease at diagnosis. All displayed data have been estimated. Estimated numbers resulted from statistical adjustment that accounted for reporting delays and missing risk-factor information, but not for incomplete reporting. Heterosexual contact is with a person known to have or to be at high risk for HIV infection.

In 2009, the estimated number of diagnoses of HIV infection among adult and adolescent males (32,538) in the 40 states and 5 U.S. dependent areas with confidential name-based HIV infection reporting since at least January 2006 was more than 3 times the number for females (10,255). Among males, an estimated 8% of diagnosed HIV infections were attributed to injection drug use and 4% were attributed to male-to-male sexual contact and injection drug use. Among females, 15% of diagnosed HIV infections were attributed to injection drug use.   The following 40 states have had laws or regulations requiring confidential name-based HIV infection reporting since at least January 2006: Alabama, Alaska, Arizona, Arkansas, Colorado, Connecticut, Florida, Georgia, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Michigan, Minnesota, Mississippi, Missouri, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Pennsylvania, South Carolina, South Dakota, Tennessee, Texas, Utah, Virginia, West Virginia, Wisconsin, and Wyoming. The 5 U.S. dependent areas include American Samoa, Guam, the Northern Mariana Islands, Puerto Rico and the U.S. Virgin Islands. Data include persons with a diagnosis of HIV infection regardless of stage of disease at diagnosis. All displayed data have been estimated. Estimated numbers resulted from statistical adjustment that accounted for reporting delays and missing risk-factor information, but not for incomplete reporting. Heterosexual contact is with a person known to have or to be at high risk for HIV infection.

This slide shows a comparison between male and female injection drug users (IDUs) diagnosed with HIV infection in 2009, by race/ethnicity, in the 40 states and 5 U.S. dependent areas with confidential name-based HIV infection reporting since at least January 2006. Among male IDUs, an estimated 50% were black/African American, 30% were Hispanic/Latino and 17% were white. In comparison, among female IDUs, 54% were black/African American, 26% were white, and 18% were Hispanic/Latino.   Among both sexes, American Indian/Alaska Native, Asian, Native Hawaiian/other Pacific Islander, and person reporting multiple races each comprised 1% or less of IDUs. The following 40 states have had laws or regulations requiring confidential name-based HIV infection reporting since at least January 2006: Alabama, Alaska, Arizona, Arkansas, Colorado, Connecticut, Florida, Georgia, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Michigan, Minnesota, Mississippi, Missouri, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Pennsylvania, South Carolina, South Dakota, Tennessee, Texas, Utah, Virginia, West Virginia, Wisconsin, and Wyoming. The 5 U.S. dependent areas include American Samoa, Guam, the Northern Mariana Islands, Puerto Rico and the U.S. Virgin Islands. Data include persons with a diagnosis of HIV infection regardless of stage of disease at diagnosis. All displayed data have been estimated. Estimated numbers resulted from statistical adjustment that accounted for reporting delays and missing risk-factor information, but not for incomplete reporting. Data on injection drug use among males do not include men who reported sexual contact with other men and injection drug use. Hispanics/Latinos can be of any race.

In 2009, an estimated 4,172 diagnosed HIV infections were attributed to injection drug use (IDU) in the 40 states and 5 U.S. dependent areas with confidential name-based HIV infection reporting since at least January 2006.   Approximately 52% of the diagnosed HIV infections associated with IDU were among blacks/African Americans and 25% were among Hispanics/Latinos. Most of the remaining cases were among whites (20%). American Indians/Alaska Natives, Asians, and persons reporting multiple races each accounted for approximately 1% of diagnoses of HIV infection. Native Hawaiians/other Pacific Islanders accounted for less than 1% of diagnoses. The following 40 states have had laws or regulations requiring confidential name-based HIV infection reporting since at least January 2006: Alabama, Alaska, Arizona, Arkansas, Colorado, Connecticut, Florida, Georgia, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Michigan, Minnesota, Mississippi, Missouri, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Pennsylvania, South Carolina, South Dakota, Tennessee, Texas, Utah, Virginia, West Virginia, Wisconsin, and Wyoming. The 5 U.S. dependent areas include American Samoa, Guam, the Northern Mariana Islands, Puerto Rico and the U.S. Virgin Islands. Data include persons with a diagnosis of HIV infection regardless of stage of disease at diagnosis. All displayed data have been estimated. Estimated numbers resulted from statistical adjustment that accounted for reporting delays and missing risk-factor information, but not for incomplete reporting. Data exclude men who reported sexual contact with other men and injection drug use. Hispanics/Latinos can be of any race.

In 2009, in the 40 states and 5 U.S. dependent areas with confidential name-based HIV infection reporting since at least January 2006, an estimated 2,652 adult and adolescent male injection drug users (IDUs) were diagnosed with HIV infection. Of these diagnoses, 1,336 (50%) were among black/African American males. The number of diagnoses of HIV infection among black/African American male IDUs was nearly three times as high as the number of white male IDUs (462) and nearly twice as high as the number of Hispanic/Latino male IDUs (790).   American Indians/Alaska Natives, Asians and persons reporting multiple races each accounted for approximately 1% of diagnoses of HIV infection among male IDUs. Native Hawaiians/other Pacific Islanders accounted for less than 1% of diagnoses. The following 40 states have had laws or regulations requiring confidential name-based HIV infection reporting since at least January 2006: Alabama, Alaska, Arizona, Arkansas, Colorado, Connecticut, Florida, Georgia, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Michigan, Minnesota, Mississippi, Missouri, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Pennsylvania, South Carolina, South Dakota, Tennessee, Texas, Utah, Virginia, West Virginia, Wisconsin, and Wyoming. The 5 U.S. dependent areas include American Samoa, Guam, the Northern Mariana Islands, Puerto Rico and the U.S. Virgin Islands. Data include persons with a diagnosis of HIV infection regardless of stage of disease at diagnosis. All displayed data have been estimated. Estimated numbers resulted from statistical adjustment that accounted for reporting delays and missing risk-factor information, but not for incomplete reporting. Data exclude men who reported sexual contact with other men and injection drug use. Hispanics/Latinos can be of any race.

In 2009, in the 40 states and 5 U.S. dependent areas with confidential name-based HIV infection reporting since at least January 2006, an estimated 1,520 adult and adolescent female injection drug users (IDUs) were diagnosed with HIV infection. Of these diagnoses, 827 (54%) were among black/African American females. The number of diagnoses of HIV infection among black/African American female IDUs was approximately three times as high as the number of Hispanic/Latino female IDUs (269) and more than two times as high as the number of white female IDUs (388).   American Indians/Alaska Natives and persons reporting multiple races each accounted for approximately 1% of diagnoses of HIV infection among female IDUs. Asians accounted for less than 1% of diagnoses and there were no diagnoses among Native Hawaiian/other Pacific Islander female IDUs. The following 40 states have had laws or regulations requiring confidential name-based HIV infection reporting since at least January 2006: Alabama, Alaska, Arizona, Arkansas, Colorado, Connecticut, Florida, Georgia, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Michigan, Minnesota, Mississippi, Missouri, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Pennsylvania, South Carolina, South Dakota, Tennessee, Texas, Utah, Virginia, West Virginia, Wisconsin, and Wyoming. The 5 U.S. dependent areas include American Samoa, Guam, the Northern Mariana Islands, Puerto Rico and the U.S. Virgin Islands. Data include persons with a diagnosis of HIV infection regardless of stage of disease at diagnosis. All displayed data have been estimated. Estimated numbers resulted from statistical adjustment that accounted for reporting delays and missing risk-factor information, but not for incomplete reporting. Hispanics/Latinos can be of any race.

This slide shows estimated data by IDU-related transmission category and age group, for diagnoses of HIV infection during 2009, from the 40 states and 5 U.S. dependent areas with confidential named-based HIV infection reporting since at least January 2006. Two standard transmission categories are collectively referred to as related to injection drug use (IDU-related), and these two categories are mutually exclusive: injection drug use; and male-to-male sexual contact and injection drug use. For this slide, the injection drug use category has been further separated by sex.   Overall, the number of IDU-related diagnoses of HIV infection increased as age increased. The percentage of IDU-related cases among male injection drug users generally increased with increasing age, while the percentage was generally stable among females regardless of age. The percentage of diagnoses among men who have sex with men and also inject drugs generally decreased with increasing age. The following 40 states have had laws or regulations requiring confidential name-based HIV infection reporting since at least January 2006: Alabama, Alaska, Arizona, Arkansas, Colorado, Connecticut, Florida, Georgia, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Michigan, Minnesota, Mississippi, Missouri, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Pennsylvania, South Carolina, South Dakota, Tennessee, Texas, Utah, Virginia, West Virginia, Wisconsin, and Wyoming. The 5 U.S. dependent areas include American Samoa, Guam, the Northern Mariana Islands, Puerto Rico and the U.S. Virgin Islands. Data include persons with a diagnosis of HIV infection regardless of stage of disease at diagnosis. All displayed data have been estimated. Estimated numbers resulted from statistical adjustment that accounted for reporting delays and missing risk-factor information, but not for incomplete reporting.

This slide shows diagnosed HIV infections related to injection drug use by age group and race/ethnicity in the 40 states and 5 U.S. dependent areas with confidential named-based HIV infection reporting since at least January 2006. Two standard transmission categories are collectively referred to as related to injection drug use (IDU-related), and these two categories are mutually exclusive: injection drug use; and male-to-male sexual contact and injection drug use.   Of the estimated 5,329 IDU-related diagnosed HIV infections in 2009, 48% were among blacks/African Americans, 25% were among whites, and 24% were among Hispanic/Latinos. Overall, the number of IDU-related diagnoses of HIV infection increased as age increased. The percentage of IDU-related cases among blacks/African Americans decreased with increasing age until the 25-34 age group, then increased with increasing age. The percentage of IDU-related cases among Hispanics/Latinos and among whites increased with increasing age until the 25-34 age group, then decreased with increasing age. American Indians/Alaska Natives (all age groups), Asians (all age groups) and persons reporting multiple races (all age groups) each accounted for approximately 1% of IDU-related cases. Native Hawaiians/Other Pacific Islanders (all age groups) accounted for less than 1% of IDU-related cases. The following 40 states have had laws or regulations requiring confidential name-based HIV infection reporting since at least January 2006: Alabama, Alaska, Arizona, Arkansas, Colorado, Connecticut, Florida, Georgia, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Michigan, Minnesota, Mississippi, Missouri, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Pennsylvania, South Carolina, South Dakota, Tennessee, Texas, Utah, Virginia, West Virginia, Wisconsin, and Wyoming. The 5 U.S. dependent areas include American Samoa, Guam, the Northern Mariana Islands, Puerto Rico and the U.S. Virgin Islands. Data include persons with a diagnosis of HIV infection regardless of stage of disease at diagnosis. All displayed data have been estimated. Estimated numbers resulted from statistical adjustment that accounted for reporting delays and missing risk-factor information, but not for incomplete reporting.

During 2008, an estimated 4,907 deaths occurred among adult and adolescent injection drug users (IDUs) with a diagnosis of HIV infection in the 40 states and 5 U.S. dependent areas with confidential name-based HIV infection reporting since at least January 2006. Blacks/African Americans had the highest proportion of deaths among IDUs (54%) followed by Hispanics/Latinos (25%) and whites (18%). Persons reporting multiple races accounted for approximately 3% of deaths among IDUs. American Indians/Alaska Natives, Asians and Native Hawaiians/other Pacific Islanders accounted for less than 1% of deaths each.   The following 40 states have had laws or regulations requiring confidential name-based HIV infection reporting since at least January 2006: Alabama, Alaska, Arizona, Arkansas, Colorado, Connecticut, Florida, Georgia, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Michigan, Minnesota, Mississippi, Missouri, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Pennsylvania, South Carolina, South Dakota, Tennessee, Texas, Utah, Virginia, West Virginia, Wisconsin, and Wyoming. The 5 U.S. dependent areas include American Samoa, Guam, the Northern Mariana Islands, Puerto Rico and the U.S. Virgin Islands. Data include persons with a diagnosis of HIV infection regardless of stage of disease at diagnosis. All displayed data have been estimated. Estimated numbers resulted from statistical adjustment that accounted for reporting delays and missing risk-factor information, but not for incomplete reporting. Data exclude men who reported sexual contact with other men and injection drug use. The Asian category includes Asian/Pacific Islander legacy cases (cases that were diagnosed and reported under the old race/ethnicity classification system). Hispanics/Latinos can be of any race.

At the end of 2008, an estimated 130,392 adult and adolescent injection drug users (IDUs) were living with a diagnosis of HIV infection in the 40 states and 5 U.S. dependent areas with confidential name-based HIV infection reporting since at least January 2006.   Approximately 52% of IDUs living with a diagnosis of HIV infection at the end of 2008 were black/African American, 27% were Hispanic/Latino, and 19% were white. Persons reporting multiple races accounted for approximately 2% of IDUs living with a diagnosis of HIV infection. American Indians/Alaska Natives, Asians, and Native Hawaiians/other Pacific Islanders accounted for less than 1% each of IDUs living with a diagnosis of HIV infection. The following 40 states have had laws or regulations requiring confidential name-based HIV infection reporting since at least January 2006: Alabama, Alaska, Arizona, Arkansas, Colorado, Connecticut, Florida, Georgia, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Michigan, Minnesota, Mississippi, Missouri, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Pennsylvania, South Carolina, South Dakota, Tennessee, Texas, Utah, Virginia, West Virginia, Wisconsin, and Wyoming. The 5 U.S. dependent areas include American Samoa, Guam, the Northern Mariana Islands, Puerto Rico and the U.S. Virgin Islands. Data include persons with a diagnosis of HIV infection regardless of stage of disease at diagnosis. All displayed data have been estimated. Estimated numbers resulted from statistical adjustment that accounted for reporting delays and missing risk-factor information, but not for incomplete reporting. Data exclude men who reported sexual contact with other men and injection drug use. The Asian category includes Asian/Pacific Islander legacy cases (cases that were diagnosed and reported under the old race/ethnicity classification system). Hispanics/Latinos can be of any race.

The estimated number of AIDS diagnoses among injection drug users (IDUs) in the United States and dependent areas increased during 1985–1993, and decreased thereafter. During 1993, there were an estimated 24,509 AIDS diagnoses among IDUs. In 2009, there were an estimated 5,189 AIDS diagnoses among IDUs. Among men who have sex with men who also inject drugs, 7,728 were diagnosed with AIDS in 1992. After 1992, a decreasing trend occurred in this group. In 2009, an estimated 1,608 men who have sex with men who also inject drugs received an AIDS diagnosis.   Estimated numbers resulted from statistical adjustment that accounted for reporting delays and missing risk-factor information, but not for incomplete reporting. Heterosexual contact is with a person known to have or to be at high risk for HIV infection.

In 2009, the estimated number of AIDS diagnoses among male adults and adolescents (26,102) in the United States and dependent areas was nearly 3 times the number among females (8,879). Among males, 12% of AIDS cases were attributed to injection drug use, and 6% to male-to-male sexual contact and injection drug use. Among females, 22% of AIDS cases were attributed to injection drug use.   Estimated numbers resulted from statistical adjustment that accounted for reporting delays and missing risk-factor information, but not for incomplete reporting. Heterosexual contact is with a person known to have or to be at high risk for HIV infection.

During 1985–2009, the percentage of AIDS cases attributed to injection drug use (IDU) ranged from a minimum of 15% to a maximum of 32% in the United States and dependent areas: 20% in 1985 with a gradual increase through 1993; 32% in 1993; gradual decrease from 1994-onward; and 15% in 2009. The greatest number of AIDS diagnoses among IDUs was 24,509 in 1993.   Estimated numbers resulted from statistical adjustment that accounted for reporting delays and missing risk-factor information, but not for incomplete reporting. Data exclude men who reported sexual contact with other men and injection drug use.

This graph shows the racial/ethnic trends in estimated AIDS diagnoses in the United States and dependent areas during 1985–2009 among adult and adolescent injection drug users (IDUs). Rates by race and ethnicity, important for understanding the impact of the epidemic on racial/ethnic groups, are not presented due to the difficulty in obtaining the total number of IDUs in each race/ethnicity category.   Noteworthy is the decline from 1992 through 2009 in AIDS diagnoses among black/African American IDUs. Despite this decline, the largest number of AIDS diagnoses among IDUs each year was in blacks/African Americans. The second largest number of AIDS diagnoses among IDUs was in Hispanics/Latinos, followed by whites. Very few AIDS diagnoses among IDUs were in American Indians/Alaska Natives, Asians, Native Hawaiians/other Pacific Islanders, and persons reporting multiple races. All displayed data have been estimated. Estimated numbers resulted from statistical adjustment that accounted for reporting delays and missing risk-factor information, but not for incomplete reporting. Data exclude men who reported sexual contact with other men and injection drug use. The Asian category includes Asian/Pacific Islander legacy cases (cases that were diagnosed and reported under the old race/ethnicity classification system). Hispanics/Latinos can be of any race.

In 2009, an estimated 3,207 AIDS diagnoses were among adult and adolescent male injection drug users (IDUs) in the United States and dependent areas. Of AIDS diagnoses among IDUs, an estimated 1,654 (52%) were in black/African American males. The number of AIDS diagnoses in black/African American male IDUs was nearly twice the number of AIDS diagnoses in Hispanic/Latino male IDUs, and more than three times as high as the number in white male IDUs.   All displayed data have been estimated. Estimated numbers resulted from statistical adjustment that accounted for reporting delays and missing risk-factor information, but not for incomplete reporting. Data exclude men who reported sexual contact with other men and injection drug use. The Asian category includes Asian/Pacific Islander legacy cases (cases that were diagnosed and reported under the old race/ethnicity classification system). Hispanics/Latinos can be of any race.

In 2009, an estimated 1,982 AIDS diagnoses were among adult and adolescent female injection drug users (IDUs) in the United States and dependent areas. Of AIDS diagnoses among female IDUs, an estimated 1,135 (57%) were in black/African American females. The number of AIDS diagnoses in black/African American female IDUs was nearly three times as high as the number of AIDS diagnoses in white female IDUs, and more than three times as high as the number in Hispanic/Latino female IDUs.   All displayed data have been estimated. Estimated numbers resulted from statistical adjustment that accounted for reporting delays and missing risk-factor information, but not for incomplete reporting. The Asian category includes Asian/Pacific Islander legacy cases (cases that were diagnosed and reported under the old race/ethnicity classification system). Hispanics/Latinos can be of any race.

In 2009, an estimated 5,189 AIDS diagnoses were among injection drug users (IDUs) residing in the United States (includes 50 states and District of Columbia) and 5 U.S. dependent areas. Of these, the greatest number of AIDS diagnoses was among IDUs in the South (1,936), followed by IDUs in the Northeast (1,892). In all regions except the West, the largest percentage of AIDS diagnoses among IDUs was in blacks/African Americans. In the Northeast, blacks/African Americans accounted for 1,010 (53%), and Hispanics/Latinos accounted for 576 (30%) of AIDS diagnoses among IDUs. Inter-region comparisons of estimated numbers of AIDS diagnoses should be made cautiously because the four regions and the U.S. dependent areas vary by number of jurisdictions and by population size. In the South, blacks/African Americans accounted for 1,317 (68%) of AIDS diagnoses among IDUs and whites accounted for 364 (19%) of AIDS diagnoses among IDUs.   Regions of residence are defined as follows: Northeast—Connecticut, Maine, Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, Vermont Midwest—Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri, Nebraska, North Dakota, Ohio, South Dakota, Wisconsin South—Alabama, Arkansas, Delaware, District of Columbia, Florida, Georgia, Kentucky, Louisiana, Maryland, Mississippi, North Carolina, Oklahoma, South Carolina, Tennessee, Texas, Virginia, West Virginia West—Alaska, Arizona, California, Colorado, Hawaii, Idaho, Montana, Nevada, New Mexico, Oregon, Utah, Washington, Wyoming U.S. dependent areas—American Samoa, Guam, the Northern Mariana Islands, Puerto Rico and the U.S. Virgin Islands All displayed data have been estimated. Estimated numbers resulted from statistical adjustment that accounted for reporting delays and missing risk-factor information, but not for incomplete reporting. Data exclude men who reported sexual contact with other men and injection drug use. The Asian category includes Asian/Pacific Islander legacy cases (cases that were diagnosed and reported under the old race/ethnicity classification system). Hispanics/Latinos can be of any race.

At the end of 2008, an estimated 103,269 adult and adolescent injection drug users (IDUs) were living with an AIDS diagnosis in the United States and dependent areas.   Approximately 53% of IDUs living with an AIDS diagnosis at the end of 2008 were black/African American, 26% were Hispanic/Latino, and 19% were white. Persons reporting multiple races accounted for approximately 2% of IDUs living with an AIDS diagnosis. American Indians/Alaska Natives, Asians, and Native Hawaiians/other Pacific Islanders accounted for less than 1% each of IDUs living with an AIDS diagnosis. All displayed data have been estimated. Estimated numbers resulted from statistical adjustment that accounted for reporting delays and missing risk-factor information, but not for incomplete reporting. Data exclude men who reported sexual contact with other men and injection drug use. The Asian category includes Asian/Pacific Islander legacy cases (cases that were diagnosed and reported under the old race/ethnicity classification system). Hispanics/Latinos can be of any race.